S&P Futures
3,635.75+3.00(+0.08%)Dow Futures
29,978.00-20.00(-0.07%)Nasdaq Futures
12,119.25+43.25(+0.36%)
GlycoMimetics, Inc. (GLYC)
Chart Events
Performance Outlook
| Previous Close | 3.6500 |
| Open | 3.8500 |
| Bid | 3.5000 x 800 |
| Ask | 4.8900 x 1300 |
| Day's Range | 3.5400 - 3.8590 |
| 52 Week Range | 1.8200 - 6.2900 |
| Volume | 1,157,799 |
| Avg. Volume | 419,593 |
| Market Cap | 172.184M |
| Beta (5Y Monthly) | 2.43 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1260 |
| Earnings Date | Nov 06, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.00 |
Fair Value
Related Research
- Business Wire
GlycoMimetics to Present at Two Upcoming Virtual Healthcare Investor Conferences
GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that CEO Rachel King plans to present an overview of the company at the upcoming Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17 and the Jefferies Virtual London Healthcare Conference on Thursday, November 19. Both presentations will be available on the Company’s website, under the Investors tab. Details are as follows:
- Motley Fool
GlycoMimetics Inc (GLYC) Q3 2020 Earnings Call Transcript
Good Morning and thank you all for joining GlycoMimetics corporate update conference call. Brian will provide an overview of the company's financial position and we'll then open the call for Q&A. Our Co-Founder and Chief Scientific Officer, Dr. John Magnani will join us in the Q&A to address your questions on the emerging preclinical data.
- Business Wire
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2020
GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the third quarter ended September 30, 2020, and highlighted recent company events. Cash and cash equivalents at September 30, 2020 were $142.9 million.
